Zusammenfassung
Weichteilsarkome (WTS) und Weichteiltumoren unterschiedlicher Malignität stellen eine heterogene Gruppe von Tumoren dar, die primär in den Weichteilen entstehen und sich wahrscheinlich aus pluripotenten mesenchymalen Zellen entwickeln. Sie bilden die viertgrößte Gruppe solider Tumoren im Kindesalter. Der häufigste bei Kindern auftretende Tumor aus der Gruppe der WTS ist das Rhabdomyosarkom (RMS). Ziel dieses Kapitels ist es, die Prinzipien der Diagnostik und Behandlung der WTS in den Therapieoptimierungsstudien der GPOH und anderer Studiengruppen darzustellen.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Literatur
Armenian SH et al. (2015) Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol 16: e123–e136
Arndt CA, Stoner JA, Hawkins DS et al. (2009) Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children’s oncology group study D9803. J Clin Oncol 27: 5182–5188
Benesch M, Wardelmann E, Ferrari A et al. (2009) Gastrointestinal stromal tumors (GIST) in children and adolescents: a comprehensive review of the current literature. Pediatr Blood Cancer 53: 1171–1179
Breitfeld PP, Lyden E, Raney RB et al. (2001) Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group. J Pediatr Hematol Oncol 23: 225–233
Carli M, Colombatti R, Oberlin O et al. (1999) High-dose melphalan with autologous stem-cell rescue in metastatic rhabdomyosarcoma. J Clin Oncol 17: 2796–2803
Carli M, Colombatti R, Oberlin O et al. (2004) European intergroup studies (MMT4-89 and MMT4-91) on childhood metastatic rhabdomyosarcoma: final results and analysis of prognostic factors. J Clin Oncol 22: 4787–4794
Carli M, Ferrari A, Mattke A et al. (2005) Pediatric malignant peripheral nerve sheath tumor: the Italian and German soft tissue sarcoma cooperative group. J Clin Oncol 23: 8422–8430
Casanova M, Ferrari A, Collini P et al. (2006) Epithelioid sarcoma in children and adolescents: a report from the Italian Soft Tissue Sarcoma Committee. Cancer 106: 708–717
Chavez C, Hoffmann MA (2013) Complete remission of ALK-negative plasma cell granuloma (inflammatory myofibroblastic tumor) of the lung induced by celecoxib: a case report and review of the literature. Oncol Lett 5: 1672–1676
Coindre JM, Trojani M, Contesso G et al. (1986) Reproducibility of a histopathologic grading system for adult soft tissue sarcoma. Cancer 58: 306–309
Crist WM, Anderson JR, Meza JL et al. (2001) Intergroup rhabdomyosarcoma study-IV: results for patients with non-metastatic disease. J Clin Oncol 19: 3091–3102
CWS-Guidance (2014) Version 1.6.1 der CWS-guidance (CWS-guidance for risk adapted treatment of soft tissue sarcoma and soft tissue tumours in children, adolescents and young adults). CWS-Studienzentrale, Stuttgart
Dantonello TM, Int-Veen C, Leuschner I et al. (2008) Mesenchymal chondrosarcoma of soft tissues and bone in children, adolescents, and young adults: experiences of the CWS and COSS study groups. Cancer 112: 2424–2431
Dantonello TM, Int-Veen C, Harms D et al. (2009) Cooperative trial CWS-91 for localized soft tissue sarcoma in children, adolescents, and young adults. J Clin Oncol 27: 1446–1455
Dehner LP, Watterson J, Priest J (1995) Pleuropulmonary blastoma. A unique intrathoracic pulmonary neoplasm of childhood. Perspect Pediatr Pathol 18: 214–226
Davicioni E, Anderson JR, Buckley JD et al. (2010) Gene expression profiling for survival prediction in pediatric rhabdomyosarcomas: a report from the children’s oncology group. J Clin Oncol 28: 1240–1246
Escobar C, Munker R, Thomas JO et al. (2012) Update on desmoid tumors. Ann Oncol 23: 562–569
Ferrari A, Chi YY, De Salvo GL etal. (2017) Surgery alone is sufficient therapy for children and adolescents with low-risk synovial sarcoma: A joint analysis from the European paediatric soft tissue sarcoma Study Group and the Children’s Oncology Group. Eur J Cancer 78: 1–6
Ferrari A, De Salvo GL, Brennan B etal. (2015) Synovial sarcoma in children and adolescents: the European Pediatric Soft Tissue Sarcoma Study Group prospective trial (EpSSG NRSTS 2005). Ann Oncol 26: 567–572
Fletcher CDM, Bridge JA, Hogendoorn P, Mertens F (2013) WHO Classification of Tumours of Soft Tissue and Bone, 4th edn. World Health Organization, Genf
Grier HE, Krailo MD, Tarbell NJ et al. (2003) Addition of ifosfamide and etoposide to standard chemotherapy for Ewing’s sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 348: 694–701
Hermanek P (1997) International Union Against Cancer: TNM atlas: illustrated guide to the TNM/pTNM classification of malignant tumours, 4th edn. Springer, Berlin New York
Hill DA, Ivanovich J, Priest JR et al. (2009) DICER1 mutations in familial pleuropulmonary blastoma. Science 325(5943): 965
Holtkamp N, Malzer E, Zietsch J et al. (2008) EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapy. Neuro Oncol 10: 946–957
Jilong Y, Jian W, Xiaoyan Z et al. (2007) Analysis of APC/beta-catenin genes mutations and Wnt signalling pathway in desmoid-type fibromatosis. Pathology 39: 319–325
Kim A, Widemann BC, Krailo M et al. (2015) Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children’s Oncology Group. Pediatr Blood Cancer 62: 1562–1566
Koscielniak E, Harms D, Henze G et al. (1999) Results of treatment for soft tissue sarcoma in childhood and adolescence: a final report of the German Cooperative Soft Tissue Sarcoma Study CWS-86. J Clin Oncol 17: 3706–3719
Koscielniak E, Klingebiel T, Gross-Wieltsch U et al. (2002) Transplantation of a megadose of full-haplotype mismatched hematopoetic stem cell (HSCT) as a treatment of metastatic relapse of Ewing sarcoma. Bone Marrow Transplant 29: 191
Koscielniak E, Kosztyla D, Dantonello T et al. (2013) Report of the CWS 2002P study: treatment results for soft tissue sarcomas (STS) in childhood and adolescence. 45th Congress of the International Society of Paediatric Oncology (SIOP) 2013. Hong Kong (China), 25th–28th September 2013. Abstracts. Pediatr Blood Cancer 60 (Suppl 3): 32
Kratz CP, Steinemann D, Niemeyer CM et al. (2007) Uniparental disomy at chromosome 11p15.5 followed by HRAS mutations in embryonal rhabdomyosarcoma: lessons from Costello syndrome. Hum Mol Genet 16: 374–379
Kummar S (2013) Cediranib for metastatic alveolar soft part sarcoma. JClin Oncol 31: 2296–2302
Ladra MM, Szymonifka JD, Mahajan A et al. (2014) Preliminary results of a phase II trial of proton radiotherapy for pediatric rhabdomyosarcoma. J Clin Oncol 32: 3761–3770
Mattke AC, Bailey EJ, Schuck A et al. (2009) Does the time-point of relapse influence outcome in pediatric rhabdomyosarcomas? Pediatr Blood Cancer 52: 772–776
Meazza C, Bisogno G, Gronchi A et al. (2010) Aggressive fibromatosis in children and adolescents: the Italian experience. Cancer 116: 233–240
Mentzel T (2010) Spindle cell rhabdomyosarcoma in adults: a new entity in the spectrum of malignat mesenchymal tumors of soft tissues. Pathologe 91–96
Missiaglia E, Williamson D, Chisholm J et al. (2012) PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification. J Clin Oncol 30: 1670–1677
Mossé YP, Lim MS, Voss SD et al. (2013) Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children’s Oncology Group phase 1 consortium study. Lancet Oncology 14: 472–480
Mohajeri A, Tayebwa J, Collin A et al. (2013) Comprehensive genetic analysis identifies a pathognomonic NAB2/STAT6 fusion gene, nonrandom secondary genomic imbalances, and a characteristic gene expression profile in solitary fibrous tumor. Genes Chromosomes Cancer 52(10): 873–886
Oberlin O, Rey A, Sanchez de Toledo J et al. (2012) Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: long-term results from the International Society of Pediatric Oncology MMT95 study. J Clin Oncol 30: 2457–2465
Onyango P, Feinberg AP (2011) A nucleolar protein, H19 opposite tumor suppressor (HOTS), is a tumor growth inhibitor encoded by a human imprinted H19 antisense transcript. Proc Natl Acad Sci 108: 16759–16764
Pratt CB, Pappo AS, Gieser P et al. (1999) Role of adjuvant chemotherapy in the treatment of surgically resected pediatric nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study. J Clin Oncol 17: 1219
Priest JR, Hill DA, Williams GM et al. (2006) Type I pleuropulmonary blastoma: a report from the International Pleuropulmonary Blastoma Registry. J Clin Oncol 24: 4492–4498
Reilly KM (2013) Extending the convergence of canonical WNT signaling and classic cancer pathways for treatment of malignant peripheral nerve sheath tumors. Cancer Discov 3: 610–612
Ripperger T, Bielack SS, Borkhardt A et al. (2017) Childhood cancer predisposition syndromes-A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology. Am J Med Genet A 173: 1017–1037
Rosen G, Forscher C, Lowenbraun S et al. (1994) Synovial sarcoma. Uniform response of metastases to high dose ifosfamide. Cancer 73: 2506–2511
Schuck A, Mattke AC, Schmidt B et al. (2004) Group II rhabdomyosarcoma and rhabdomyosarcomalike tumors: is radiotherapy necessary? J Clin Oncol 22: 143–149
Sparber-Sauer M, Seitz G, Kirsch S et al.; CWS Study Group (2017) The impact of local control in the treatment of type II/III pleuropulmonary blastoma. Experience of the Cooperative Weichteilsarkom Studiengruppe (CWS). J Surg Oncol 115: 164–172
Stevens MC, Rey A, Bouvet N et al. (2005) Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology – SIOP Malignant Mesenchymal Tumor 89. J Clin Oncol 23: 2618–2628
UICC (1982) Union Internationale Contre le Cancer. TNM classification of paedriatric tumours. UICC, Genf
Vinod R, Shreyaskumar P (2013) Vascular sarcomas. Curr Oncol Rep 15: 3: 347–355
Wachtel M, Runge T, Leuschner I et al. (2006) Subtype and prognostic classification of rhabdomyosarcoma by immunohistochemistry. J Clin Oncol 24: 816–822
Weigel BJ, Breitfeld PP, Hawkins D et al. (2001) Role of high-dose chemotherapy with hematopoietic stem cell rescue in the treatment of metastatic or recurrent rhabdomyosarcoma. J Pediatr Hematol Oncol 23: 272–276
Weigel BJ, Lyden E, Anderson JR et al. (2016) Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children’s Oncology Group. J Clin Oncol 34: 117–122
Worst BC, van Tilburg CM, Balasubramanian GP et al. (2016) Next-generation personalised medicine for high-risk paediatric cancer patients – The INFORM pilot study. Eur J Cancer 65: 91–101
Author information
Authors and Affiliations
Corresponding authors
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer-Verlag GmbH Deutschland
About this chapter
Cite this chapter
Koscielniak, E., Klingebiel, T. (2018). Weichteilsarkome. In: Niemeyer, C., Eggert, A. (eds) Pädiatrische Hämatologie und Onkologie. Springer Reference Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-43686-8_27
Download citation
DOI: https://doi.org/10.1007/978-3-662-43686-8_27
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-43685-1
Online ISBN: 978-3-662-43686-8
eBook Packages: Medicine (German Language)